SCHEMBL23326744

SCHEMBL23326744

Cn1c(=O)c(Br)cc2c(Cl)ncnc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.33
CYP1A2 P05177 3/20 0.33
TSHR P16473 2/20 0.33
CYP2C9 P11712 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
USP2 O75604 1/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
PABPC1 P11940 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPT P10636 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
ADK P55263 1/20 0.32
GRM4 Q14833 1/20 0.31
SELE P16581 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861403 1.00 HSD17B10 (0.33) HSD17B10CYP1A2TSHRCYP2C9SLC22A12
SCHEMBL23326640 0.81 CYP1A2 (0.33) HSD17B10CYP1A2TSHRCYP2C9USP2
SCHEMBL29861748 0.81 CYP1A2 (0.33) HSD17B10CYP1A2TSHRCYP2C9USP2
SCHEMBL29861884 0.81 EGFR (0.35) HSD17B10CYP1A2TSHRCYP2C9SLC22A12
SCHEMBL24672007 0.81 SLC22A12 (0.39) HSD17B10CYP1A2TSHRCYP2C9SLC22A12
SCHEMBL23326642 0.81 EGFR (0.35) HSD17B10CYP1A2TSHRCYP2C9SLC22A12
SCHEMBL5560155 0.80 ADORA2A (0.35) SLC22A12HTTALDH1A1MAPTADORA2A
SCHEMBL25396743 0.78 ALDH1A1 (0.38) HSD17B10CYP1A2TSHRHPGDALDH1A1
SCHEMBL29910267 0.77 KDM4E (0.35) HSD17B10TSHRHPGDHTTALDH1A1
SCHEMBL23326638 0.77 KDM4E (0.35) HSD17B10TSHRHPGDHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
CN-116669738-A Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2023-08-29 CN disclosed
CN-116425742-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2023-07-14 CN disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 EP disclosed
WO-2022170802-A1 PYRIMIDO-PYRIDONE DERIVATIVE AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2022-08-18 WO disclosed
WO-2022170802-A1 PYRIMIDO-PYRIDONE DERIVATIVE AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2022-08-18 WO disclosed
CN-114901662-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2022-08-12 CN disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 HSD17B10 1824/4885CYP1A2 1997/4885TSHR 2547/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 HSD17B10 3031/4885CYP1A2 2086/4885TSHR 2669/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 HSD17B10 3031/4885CYP1A2 2086/4885TSHR 2669/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 HSD17B10 3031/4885CYP1A2 2086/4885TSHR 2669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.